Best Immunotherapy Companies in Ile de France, France
The 37 best Immunotherapy companies in Ile de France, France in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Abivax.
Our analysis of 50 Immunotherapy companies
$8.8b in tracked funding; 69% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Immunotherapy companies in Ile de France
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Abivax Developer of therapeutics for chronic inflammatory diseases | $320M | 42 mo ago | 26 | — | Public | 616 patents Small-molecule quinoline/phenyl derivatives for antiviral and anti-inflammatory therapies | 1 launch |
| 2 | Cellectis Developer of cancer immunotherapies based on gene-edited CAR T-cells 64Patents top 20%Funding top 25%Product top 29%Innovation top 30% All 11 signals ▾Patentstop 20% Fundingtop 25% Producttop 29% Innovationtop 30% Newstop 33% Markettop 38% Moattop 41% Globaltop 45% Growthtop 48% Talentbottom 49% Techbottom 46% Patents: 1,579 patents matched (strict assignee match) · 326 filings since 2022 vs 610 in 2017-21 Funding: Raised $267M across 3 rounds · 3 rounds over 12 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $267M | 28 mo ago | 236 | Andre Choulika Chief Executive Officer | Public | 1,572 patents Engineered CAR‑T and gene‑edited immune cells for cancer immunotherapy. | — |
| 3 | Inotrem Developer of peptide immunotherapies for treating septic shock and acute myocardial infarction | $122M | 34 mo ago | 35 | Marc Derive Co-Founder and CSO | Series B | 52 patents TREM‑1 targeted therapeutics and diagnostic assays for inflammation, sepsis, and cardiovascular risk | — |
| 4 | Mnemo Therapeutics Developer of cell therapy platforms for tumors and blood cancer | $91M | 63 mo ago | 56 | Alain Maiore Co-Founder & ex-CEO | Series A | 58 patents Neoantigen peptide-based cancer immunotherapy and epigenetic modulation of immune cells | — |
| 5 | DBV Technologies Developer of products for the treatment of various kinds of food allergies 57Product top 24%Funding top 31%News top 31%Partners top 31% All 13 signals ▾Producttop 24% Fundingtop 31% Newstop 31% Partnerstop 31% Talenttop 32% Growthtop 38% Markettop 42% Moattop 42% Globaltop 45% Fin. healthtop 45% Techtop 49% Innovationbottom 37% Patentsbottom 31% Product: 2 distinct product lines · Company stage: Public Funding: Raised $68.9M across 7 rounds · 7 rounds over 20 yrs (0.3/yr) rank vs industry peers · Fliar Intelligence Index 57/100 | $69M | 17 mo ago | 88 | Pierre-Henri Benhamou Co-Founder & CEO | Public | 8 patents Transdermal patch technologies for immunotherapy, allergy desensitization, and protein delivery | 1 award |
| 6 | TheraVectys Developer of vaccines to treat infectious diseases and cancer caused by HTLV-1 infection | $62M | 67 mo ago | 19 | Ye Tian CEO | Series D | 176 patents Lentiviral vector platforms for viral antigen vaccines and cancer immunotherapy | — |
| 7 | Egle Therapeutics Provider of T cells based therapeutics for oncology and autoimmune diseases 45Funding top 34%Talent top 38%Moat top 39%Patents top 40% All 7 signals ▾Fundingtop 34% Talenttop 38% Moattop 39% Patentstop 40% Innovationbottom 49% Marketbottom 44% Globalbottom 43% Funding: Raised $46.6M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 45/100 | $47M | 18 mo ago | 28 | Eliane Piaggio Co-Founder | Series A | 11 patents Engineered cytokine variants and fusion immunotherapeutics for cancer immunotherapy | — |
| 8 | Genticel Developer of immunotherapies to treat infectious diseases and cervical cancer using CyaA vector technology | $41M | 160 mo ago | 32 | — | Series C | 50 patents Bacterial toxin-derived chimeric proteins for vaccine and immunotherapy antigen delivery | — |
| 9 | Acticor Biotech Developing immunotherapeutics for treating ischemic stroke | $31M | 82 mo ago | 29 | Gilles Avenard CEO | Public | 58 patents Anti‑GPVI antibody therapeutics for cardiovascular disease and platelet aggregation inhibition | — |
| 10 | Advesya Developer of therapies for the treatment of cancer and autoimmune diseases | $26M | 56 mo ago | — | Ksenija Pavletic Chief Executive Officer | Series B | 8 patents Antibody‑drug conjugates and CAR‑T cells targeting IL‑1RAP for cancer therapy | — |
| 11 | Tridek One Provider of therapeutics for immuno-inflammatory diseases | $19M | 48 mo ago | 5 | — | Series A | — | — |
| 12 | Neovacs CDMO focused on manufacturing of vaccines | $18M | 93 mo ago | — | Hugo Brugiere CEO | Public | 168 patents Cytokine-modulating immunotherapies and mRNA vaccines targeting IL‑4/IL‑13 pathways | — |
| 13 | Ermium Therapeutics Developer of therapies for auto-immune inflammatory diseases | $13M | 50 mo ago | 9 | — | Series A | 9 patents Small-molecule CXCR4 receptor modulators based on cyclic isothiourea scaffolds | — |
| 14 | LiMM Therapeutics Providers of therapeutics based on neuronal and innate lymphoid cells | $9M | 59 mo ago | 8 | Henrique Veiga Fernandes Founder | Seed | 7 patents Therapeutic modulation of innate lymphoid type 2 (ILC2) cells for disease treatment | — |
| 15 | InnaVirvax Vaccines for HIV and other infectious diseases | $9M | 134 mo ago | — | Joel Crouzet CEO & Co-Founder | Deadpooled | 51 patents HIV vaccine peptide‑carrier conjugates and related immuno‑diagnostic kits. | — |
| 16 | Oncovita Developer of virus-derived vaccine technology to treat cancer | $9M | 33 mo ago | 2 | Frederic Tangy Co-Founder | Series A | — | 1 partnership |
| 17 | Hephaitos Pharma Developer of immunotherapies for the treatment of cancer | $7M | 28 mo ago | — | Alexey Novikov Co-Founder | Seed | — | — |
| 18 | Peptinov Developer of anti-cytokine immunotherapies for the treatment of chronic inflammatory diseases | $6M | 33 mo ago | 8 | Rene Azoulai CEO | Series A | 33 patents Therapeutic peptide vaccines and antibody platforms targeting inflammatory cytokines and lymphocyte selection. | — |
| 19 | Stimunity Virus like particles for non-responsive cancers | $4M | 75 mo ago | 4 | — | Seed | 6 patents Therapeutic peptide/antibody compositions for cancer immunotherapy applications | — |
| 20 | Honing Biosciences Developer of cell-based therapies to treat cancer and chronic diseases | $2M | 74 mo ago | — | Abdelkader Bousabaa Founder | Deadpooled | 13 patents Therapeutic single-domain antibodies (nanobodies) targeting HER2 and protein trafficking control | — |
| 21 | IPSirius Developer of immunotherapies for cancer treatment | $2M | 47 mo ago | — | Annelise Griscelli Co-Founder | Funding Raised | — | — |
| 22 | Biomunex Developer of antibody therapeutics for the treatment of cancer | $2M | 64 mo ago | 14 | Pierre-Emmanuel Gerard President and Founder | Series A | — | 2 job openings · 2 internships |
Top 12 Immunotherapy companies in Ile de France
#1
Public · Bagneux, Ile de France · founded 2002 · 88 employees$68.9Mraised▾
Developer of products for the treatment of various kinds of food allergies. It is a clinical-stage biopharmaceutical company, engages in the R&D of epicutaneous immunotherapy products. The company provides Diallertest Milk, a diagnostic product for the detection of cow’s milk protein allergy (CMPA) in children. Its products include Viaskin Peanut, an immunotherapy product for the treatment of peanut allergies; Viaskin Milk for the treatment of CMPA and milk-induced eosinophilic esophagitis; and Viaskin Egg, a development program for the treatment of hen’s egg allergy.
- Apr 2025Post IPO$306.9M
- Jun 2022Post IPO$194M
- May 2016Post IPO$111.2M
- Jan 2013Grant (prize money)—
#2
Series A · Paris, Ile de France · founded 2020 · 28 employees$46.6Mraised▾
Provider of T cells-based therapeutics for oncology and autoimmune disease. The company offers computational-based IL-2 modified variants and translational-based therapeutic Treg targets to restore the immune response.
- Mar 2025Grant (prize money)$10.1M
- Oct 2021Series A$46.6M
#3
Public · Paris, Ile de France · founded 1999 · 236 employees$267.4Mraised▾
Developer of cancer immunotherapies based on gene-edited CAR T-cells. The company is developing products based on TALEN, its proprietary gene-editing technology, and PulseAgile, it's pioneering electroporation system to target cancer cells. It develops UCART products to treat multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), multiple myeloma (MM), Hodgkin lymphoma (HL), and non-Hodgkin lymphoma (NHL).
- May 2024Post IPO$140M
- Nov 2023Post IPO$105M
- Mar 2014Post IPO$22.4M
#4
Series B · Paris, Ile de France · founded 2013 · 35 employees$122.5Mraised▾
Inotrem is developing peptide immunotherapies for treating septic shock and acute myocardial infarction. The company is developing drugs that target the TREM-1 pathway. The company's lead candidate, Motrem, is a TREM-1 inhibitor and is a 12 amino-acid peptide, acting as a decoy receptor and interfering with the binding of TREM-1 and its ligand. It is being investigated for septic shock, and for acute myocardial infarction. The drug is in phase I trials.
- Nov 2023Grant (prize money)—
- Dec 2022Grant (prize money)—
- Feb 2020Conventional Debt$15.3M
- Feb 2020Series B$5.5M
#5
Public · Paris, Ile de France · founded 2014 · 26 employees$319.6Mraised▾
Developer of therapeutics for chronic inflammatory diseases. The lead drug candidate obefazimod is an oral, first-and-only small molecule with a novel mechanism of action that demonstrates enhanced expression of miR-124, which plays a critical role in the regulation of the inflammatory response. It is also develops products for Ulcerative Colitis, crohn's disease, and more.
- Feb 2023Post IPO$138.6M
- Sep 2022Post IPO$49.1M
- Jul 2021Post IPO$96.6M
- May 2020Grant (prize money)$21.7M
#6
Seed · Orsay, Ile de France · founded 2018$7.1Mraised▾
Developer of immunotherapies for the treatment of cancer. The company has Onco-boost platform to develop immunostimulant injectable intravenous to treat metastatic and solid tumors ike Osteosarcoma.
- May 2024Seed$4.9M
- Jan 2024Seed$2.2M
- 2023Grant (prize money)$8M
- Oct 2019Grant (prize money)$55.6K
#7
Series A · Paris, Ile de France · founded 2015 · 2 employees$8.8Mraised▾
Developer of virus-derived vaccine technology to treat cancer. It offers Measovir platform that utilizes anti-cancer and immunogenic properties to produce effective new cancer treatments and vaccines.
- Nov 2023Series A$8.8M
#8
Series A · Paris, Ile de France · founded 2010 · 8 employees$6Mraised▾
Peptinov is specialized in the development of anti-cytokine immunotherapies (vaccines) for the treatment of chronic inflammatory diseases and cancer. It has developed three innovative vaccines against IL6, IL1, and IL23 cytokines, which have successfully been tested in mice and/or in monkeys. Its drug pipeline includes PPV-06 (anti-IL6 vaccine); PPV-01 (anti-IL1b vaccine); PPV-03 (anti-IL23 vaccine). It is developing these vaccines to treat chronic inflammatory diseases such as rheumatoid arthritis and systemic sclerosis. Also developing small molecule inhibitors of cytokines using the proprietary in silico drug design approach.
- Nov 2023Grant (prize money)$2.7M
- Nov 2023Series A$6M
#9
Series D · Paris, Ile de France · founded 2005 · 19 employees$62.1Mraised▾
Developer of vaccines to treat infectious diseases and cancer caused by HTLV-1 infection. By using the lentiviral immunotherapy platform the company has developed therapeutic vaccines for HIV, Hepatitis-B, Tuberculosis, and Adult T-cell Lymphoma-Leukaemia (ATL) induced by Human T-Lymphotropic Virus Type I (HTLV-1) infection.
- Feb 2021Series D$20M
- Apr 2017Series C$5.8M
- Jan 2015Grant (prize money)$2.1M
- Oct 2013Series C$19.9M
#10
Series A · Paris, Ile de France · founded 2018 · 56 employees$90.9Mraised▾
Developer of cell therapy platforms for tumors and blood cancers. The company has EnfiniT targeting and next-generation chimeric antigen receptors T cell therapy platform. It identifies antigens with tumor specificity that are present in cancer cells.
- Jun 2021Series A$90.9M
#11
Series A · Evry Courcouronnes, Ile de France · founded 2018 · 5 employees$19.5Mraised▾
Provider of therapeutics for immuno-inflammatory diseases. It offers a flagship product CD31 or PECAM1 which is found in all immune and endothelial cells for modulating immune activation response. The product is involved in the inhibition of PTK-dependent cellular pathways signals along with the activation of PTP-dependent signaling which helps in immunomodulation.
- Sep 2022Series A$16.1M
- Jun 2019Seed$3.4M
#12
Series B · Paris, Ile de France · founded 2020$26.1Mraised▾
Developer of therapies for the treatment of cancer and autoimmune diseases. It offers therapeutics that targets IL-1RAP, a unique antigen, which is upregulated in various cancers and autoimmune conditions. It offers CCTx-001 an IL-1RAP directed genetically modified autologous T-cell immunotherapy for the treatment of AML and ADV-101 is an ADC composed of humanized IgG1 monoclonal antibody for hematological and solid malignancies.
- Jan 2022Series B$26.1M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Immunotherapy coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Immunology & Immunotherapy is moving in France
A read on the academic research around Immunology & Immunotherapy — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,557 France-affiliated papers.
- Inserm395
- Centre National de la Recherche Scientifique280
- Assistance Publique – Hôpitaux de Paris237
- Institut Gustave Roussy139
- Aix-Marseille Université81
- Immune system11→130
- Cancer immunotherapy2→42
- Cancer research10→36
- Cytotoxic T cell4→28
- Cancer7→30
- Immune system21→187
- Oncology9→129
- Internal medicine12→123
- Cancer12→93
- Pembrolizumab5→66
- Immune system6→63
- Cancer6→44
- Oncology3→27
- Disease2→25
- Clinical trial1→22
Where immunology is researched across France
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing immunology patents in France
France immunology patent filing is cooling — 738 filings from 432 assignees (2016–2025), led by Cellectis, INST NAT Sante RECH MED, Centre NAT RECH Scient; annual filings 78→60.
- Cellectis305
- INST NAT Sante RECH MED212
- Centre NAT RECH Scient113
- INST Curie55
- Pasteur Institut52
- UNIV Paris Saclay40
- Roussy INST Gustave39
- Stallergenes34
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.